Claire Marie Porter is a reporter with The Cancer Letter. She joined the publication in 2024.
Before joining The Cancer Letter, Claire was a freelance health and science journalist with bylines in The Atlantic, Scientific American, The Washington Post, Undark Magazine, Popular Science, WIRED among other publications. She graduated with an M.S. in Journalism from Columbia University in 2020, where she received honors for her thesis "The Deadly Itch" on Intrahepatic Cholestasis of pregnancy.
She was a 2020 Society of Environmental Journalists grant recipient, and completed internships with Next City and National Public Radio.
She graduated from Temple University with a Bachelor’s degree in English in 2013.
Before joining The Cancer Letter, Claire was a freelance health and science journalist with bylines in The Atlantic, Scientific American, The Washington Post, Undark Magazine, Popular Science, WIRED among other publications. She graduated with an M.S. in Journalism from Columbia University in 2020, where she received honors for her thesis "The Deadly Itch" on Intrahepatic Cholestasis of pregnancy.
She was a 2020 Society of Environmental Journalists grant recipient, and completed internships with Next City and National Public Radio.
She graduated from Temple University with a Bachelor’s degree in English in 2013.
Latest Stories
Cancer Policy
Last year, the Trump administration began dismantling, RIFing, and stamping out programs and staff deemed ideological or politically motivated, halting application processes, and stripping funding opportunities.
Cancer Policy
The House of Representatives has passed an extension of Obamacare subsidies, sending the bill on to the Senate.
Cancer Policy
FDA has granted sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2 directed antibody-drug conjugate, a priority voucher via the agency’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.
Cancer Policy
FDA has released a congressionally mandated report evaluating the use of perfluoroalkyl and polyfluoroalkyl substances in cosmetic products.
The Directors
As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.
Cancer Policy
Harvey A. Risch, professor emeritus and senior research scientist at Yale School of Public Health, was named chair of the President’s Cancer Panel.
Cancer Policy
The U.S. Senate didn’t take up the Mikaela Naylon Give Kids a Chance Act after two Senate members—Bernie Sanders (I-VT) and Sen. Markwayne Mullin (R-OK)— voted “Nay,” blocking it.
Regulatory News
FDA has withdrawn a proposed rule that called for standardized testing for detecting and identifying asbestos in talc-containing cosmetic products.
Cancer Policy
The U.S. House of Representatives unanimously passed the Mikaela Naylon Give Kids A Chance Act, a bill to accelerate pediatric cancer treatments and expand access to life-saving therapies for children battling rare diseases.
Clinical Roundup
The American Cancer Society is introducing two key changes for cervical cancer screening guidelines.
Cancer Policy
Ralph Lee Abraham, a Louisiana surgeon general who implemented controversial policies and held views that have drawn significant criticism from public health experts, has quietly been installed as the second-highest official at the Centers for Disease Control and Prevention.
Free
The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...
Cancer Policy
An NIH employee who has been publicly critical of the Trump administration’s health policies said she was placed on “nondisciplinary” administrative leave when she returned to work Nov. 13 after the government reopened.
Cancer Policy
Natalie Phelps, a 43-year-old mother of two, died Nov. 9 from colorectal cancer.
Regulatory News
Top FDA officials said the agency is in the process of removing the black box safety warnings from all forms of menopausal hormone therapy, including creams, pills, and other treatments prescribed to ease the symptoms of menopause and perimenopause.
Cancer Policy
Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.
Regulatory News
George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Cancer Policy
The U.S. Preventative Services Task Force has postponed its November meeting due to the federal government shutdown.
Cancer Policy
The federal government shutdown is entering its fifth week, and funding delays are now directly affecting the healthcare system.
Cancer Policy
Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, often called “the voice of the CDC,” now has an rival publication.
Cancer Policy
Last week, President Donald Trump announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of some fertility drugs used for in-vitro fertilization, in exchange for a three-year reprieve on some of the tariffs levied on pharmaceutical imports (The Cancer Letter, Oct. 24, 2025).
Cancer Policy
Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).
Cancer Policy
With the start of open enrollment less than one week away, millions of Americans are getting their first look at the sharp increases many will pay next year if Congress fails to extend the enhanced premium tax credits that have expanded healthcare access to over 13 million people since 2021.
Cancer Policy
President Donald Trump has announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of certain fertility drugs used for in-vitro fertilization, or IVF.
Regulatory News
Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.
Cancer Policy
Millions of Americans with Affordable Care Act marketplace health insurance will face higher costs next year if Congress doesn’t extend enhanced premium tax credits that have made the plans more affordable for low- and middle-income enrollees.
The Directors
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
Cancer Policy
A report by the American Society of Clinical Oncology points to a growing challenge in cancer care access driven by a widening gap between the number of available oncologists and increasing patient demand.
Cancer Policy
President Donald Trump had threatened pharmaceutical companies with a 100% tariff, with an ultimatum set for Oct. 1.
Cancer Policy
Jim O’Neill, acting director of the Centers for Disease Control and Prevention, announced that he has signed off on a slew of recommendations that change the childhood vaccination schedule.
Cancer Policy
United for Medical Research conducted a report surveying patients and researchers on why NIH, and NIH funding matters to them.
NCI
Anthony G. Letai, accompanied by his wife Jean, was sworn in by HHS Secretary Kennedy as the 18th NCI Director on Sept. 29.Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute, has been officially named the 18th director of the National Cancer Institute.
Capitol Hill
On Oct. 1, for the first time in six years, the U.S. government shut down after Congress was unable to reach a deal to fund federal agencies for Fiscal Year 2026.
Cancer Policy
President Trump has signed an executive order to use artificial intelligence to accelerate research in pediatric cancers.
Cancer Policy
President Donald Trump has announced a multipronged effort aimed at lowering drug costs in the United States, including the creation of “TrumpRx,” a direct-to-consumer website where Americans can buy medicine at discounted prices and a sweeping deal with Pfizer to reduce the prices of many of its products.
Regulatory News
FDA has initiated the approval of leucovorin calcium tablets, rushing them to market as part of a push from the Trump administration to identify potential treatments for autism spectrum disorder.
Cancer Policy
In a press conference on Sept. 22, President Donald Trump, flanked by NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, HHS Secretary Robert Kennedy Jr., and CMS Administrator Mehmet Oz, touted that Tylenol use while pregnant is “probably” the cause of autism.
NCI
Anthony G. Letai, a physician-scientist at Harvard Medical School and Dana-Farber Cancer Institute whose research is focused on apoptosis and functional diagnostics, has been tapped by the Trump administration to become the 18th director of the National Cancer Institute.
Cancer Policy
Ousted from her position as director of the Centers for Disease Control and Prevention less than a month after her confirmation, Susan Monarez has now had the chance to tell her side of the story before Congress.
Cancer Policy
At a two-day meeting, the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted 8-3 to change the current recommendations that allow children under age 4 to receive the MMRV vaccine, a combination shot for measles, mumps, rubella and chickenpox (or varicella).
Cancer Policy
The American Association for Cancer Research released the results of a national survey measuring voters’ attitudes about federal funding for medical research, which found very high levels of support for federal funding for medical and cancer research across the electorate.
The Directors
In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from setbacks, and holding on to what they still have.
Cancer Policy
A fraught Senate Finance Committee hearing, where HHS Secretary Robert F. Kennedy Jr. clashed with Republicans and Democrats alike, has led to some fallout.
Cancer Policy
The Trump administration earlier this week released its strategy on children’s health.
Cancer Policy
Vinay Prasad has regained his role as FDA’s chief medical and scientific officer, according to an update on the agency’s website.
Cancer Policy
The U.S. House Appropriations Committee has voted along party lines passing a bill that maintains current funding levels for NIH and NCI as part of its Fiscal Year 2026 Labor, HHS, Education and Related Agencies spending bill.
Capitol Hill
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
Cancer Policy
At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.
Free
The American College of Obstetrics and Gynecology said it will no longer be accepting federal funding.
Free
The Department of Health and Human Services has announced the start of a reduction in its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority.
In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.
Cancer Policy
Laura LoomerVinay PrasadRight-wing activist Laura Loomer is demanding Vinay Prasad’s ouster from FDA, calling him a “saboteur” and “trojan [sic] horse” of the administration’s “Make America Healthy Again” initiative.
Cancer Policy
It has been more than three months since the Trump Administration froze Columbia University’s NIH funds in an attempt to crack down on “antisemitism.”
Cancer Policy
NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.
Cancer Policy
President Trump said he would impose tariffs on pharmaceutical products and semiconductors as soon as Aug. 1.
Cancer Policy
The Centers for Medicare & Medicaid Services published a proposed rule, which it says aligns with Trump’s “Big Beautiful Bill.”
Cancer Policy
The Centers for Medicare & Medicaid Services issued a proposed rule that would update Medicare payment policies and rates for hospital outpatient departments and ambulatory surgical centers, or ASCs, for calendar year 2026.
Clinical
Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.
Free
Source: NIH vigil organizerSince early May, a group of current and former NIH employees have gathered every Saturday at the Medical Center Metro station in Bethesda, MD, to mourn what they describe as the loss of scientific progress under the Trump administration.
Cancer Policy
The U.S. House of Representatives Thursday passed President Trump’s “One Big Beautiful Bill,” a sweeping legislation that makes the biggest cuts to Medicaid since the program began in the 1960s.
Cancer Policy
Researchers funded by NIH will now be required to make their scientific papers available to read for free as soon as they are published in a peer-reviewed journal.
Cancer Policy
NIH Director Jay Bhattacharya has started his own podcast called “The Director’s Desk,” where, according to the description on YouTube, he plans to host weekly conversations on scientific careers, leadership, and innovation at NIH.
Capitol Hill
Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.
Cancer Policy
Jacqueline Corrigan-Curay, the acting director of the Center for Drug Evaluation and Research wrote in an email to colleagues that she will be retiring from the agency in July.
Cancer Policy
Sen. Bill Cassidy (R-LA), a key Senate health leader, June 23 called for the meeting of the Advisory Committee on Immunization Practices to be delayed, citing concerns over the committee members’ lack of directly relevant experience and their potential bias against some vaccines.
Cancer Policy
In the fiscal year 2026 budget request, the Trump administration proposes “forward funding,” or multiyear funding, of awards.
Cancer Policy
A federal judge has called the Trump’s administration’s cancellation of NIH grants “illegal,” striking it down.
Cancer Policy
NIH Director Jay Bhattacharya has launched his own podcast called “The Director’s Desk,” where he plans to host weekly conversations on scientific careers, leadership, and innovation at NIH.
Cancer Policy
A new FDA voucher program will aim to accelerate review time for applications that are deemed to be advancing U.S. “national priorities.”
Cancer Policy
Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, who was named director of the FDA Center for Biologics Evaluation and Research in early May (The Cancer Letter, May 9, 2025), has now been also appointed chief medical and science officer at FDA, according to an internal memo obtained by The Cancer Letter.
Cancer Policy
FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.
Capitol Hill
In a 96-minute hearing in front of the Senate Appropriations Committee on the Trump administration’s budget, senators slammed NIH Director Jay Bhattacharya for not taking responsibility for the funding cuts to research and upheaval at NIH.
Free
For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.
Cancer Policy
After a sequence of events that unfolded publicly on NCI’s Instagram feed May 28, RIFed and “retired” members of the NCI communications team took to the independent social media platform BlueSky, creating an alternative and anonymous social media presence.
Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
Cancer Policy
HHS Secretary Robert F. Kennedy Jr. said he is considering a ban on government scientists publishing their work in top-tier medical journals, which he says are abed with pharmaceutical companies.
Cancer Policy
The U.S. State Department has ordered U.S. embassies and consulates around the world to halt appointments for new student visas as the Trump administration prepares to increase social media vetting for all foreign students applying to study in the U.S.
Clinical
The American Society of Clinical Oncology and Google Cloud have developed a tool called the ASCO Guidelines Assistant to help oncologists parse through and interpret clinical practice guidelines.
Cancer Policy
The U.S. House of Representatives voted on the so-called “One Big, Beautiful Bill Act,” this week which included drastic, $715 billion cuts to Medicaid that will result in at least 8.6 million people losing health insurance coverage, including cancer patients and survivors.
Cancer Policy
FDA Commissioner Marty Makary held a roundtable of independent scientific experts to discuss the safety and necessity of talc as an additive to food, drugs, and cosmetic products.
Cancer Policy
FDA—under the leadership of cyber-iconoclast and new director of the agency’s Center for Biologics Evaluation and Research, Vinay Prasad—is taking a new approach to COVID-19 vaccines.
Cancer Policy
In the ongoing escalation of the feud between Harvard University and the Trump White House has imperiled hundreds of research grants at Harvard’s medical school.
Cancer Policy
Harvard University has sued the Trump administration a second time since the start of the ongoing feud between the university and White House.
Cancer Policy
A three-judge federal appeals court has lifted a lower court order that blocked the federal government from enacting President Trump’s executive order to end collective bargaining by workers at more than a dozen federal agencies.
Capitol Hill
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Cancer Policy
Before two consecutive congressional hearings on the Trump administration’s “skinny budget” proposal on May 14, Sen. Bernie Sanders (I-VT), ranking member of the Senate Health, Education, Labor, and Pensions Committee, released a report assessing the administration’s impact on biomedical research.
Cancer Policy
The House Committee on Energy and Commerce budget reconciliation bill, which includes attacks on Medicaid and Affordable Care Act coverage and fails to extend ACA tax credits, would increase the number of uninsured people by at least 13.7 million.
Cancer Policy
The Kaiser Family Foundation has released a tracking poll compiling data from the first 100 days of the Trump administration.
Cancer Policy
Harvard amends lawsuit against Trump administration, includes additional defendants and funding cuts
Harvard University filed an amended lawsuit against the Trump administration, seeking to add two more federal agencies as defendants and to address the administration’s widening efforts to cut the university’s federal funding—now targeting over $2.6 billion and all future grants.
Regulatory News
Vinay Prasad, a MAHA-aligned hematologist-oncologist with an avid cyber following, was named director of the FDA Center for Biologics Evaluation and Research, where he will be responsible for the agency’s regulation of vaccines and biologics, including cell and gene therapies.
Cancer Policy
In a statement issued on May 1, NIH said it’s immediately halting most new grant awards to foreign partners working in US-led research consortia.
Cancer Policy
On April 21, investigators with the Women’s Health Initiative were notified that HHS planned to terminate the WHI Regional Center contracts at the end of the current fiscal year (The Cancer Letter, April 20, 2025).
Cancer Policy
A coalition of 20 attorneys general filed a lawsuit against the Trump Administration challenging the unlawful mass firing of roughly 10,000 full-time HHS employees, the consolidation of 28 HHS divisions into 15 divisions, and the closing of half of HHS’s ten regional offices. (The Cancer Letter, May 2, 2025).
Cancer Policy
Amid continued anticipation about tariffs on pharmaceuticals, President Trump has signed an executive order to prioritize the onshoring of prescription drug manufacturing as part of his “America First” agenda.
White House
An updated version of President Trump’s budget request published on May 2 comes as a disappointment for those who hoped that the White House would rethink the draconian cuts contained in an earlier, confidential version of the document that ended up being leaked to the press.
Capitol Hill
In the starkest opposition yet by Republicans to the Trump administration’s attacks on HHS agencies, senators from both parties sounded an alarm about the damage being done to biomedical research in the U.S.
“We stand at the edge of discovery, and on the brink of losing it,” said Patricia M. LoRusso, the 2024-2025 president of the American Association for Cancer Research. “I believe this is the most scientifically promising moment in the history of cancer research.”
Regulatory News
In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models.
Cancer Policy
On April 21, Women’s Health Initiative investigators were informed that HHS would be terminating the WHI Regional Center contracts at the end of the current fiscal year.
